Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | CA6 | P23280 | 5/20 | 0.44 |
| ▸ | CA5A | P35218 | 5/20 | 0.44 |
| ▸ | CA7 | P43166 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.44 |
| ▸ | CA3 | P07451 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250677 | 0.84 | TSHR (0.61) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL7228372 | 0.81 | TSHR (0.41) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL7228486 | 0.78 | TSHR (0.47) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL31670552 | 0.68 | CA12 (0.71) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL11818487 | 0.66 | TSHR (0.67) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL18423559 | 0.66 | CA1 (0.68) | CA12CA1CA2CA4CA6 | |
| SCHEMBL143826 | 0.66 | TP53 (0.65) | TSHRLMNAMAPK1ALDH1A1POLB | |
| SCHEMBL254969 | 0.66 | ALDH1A1 (0.56) | TSHRSMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL29128098 | 0.66 | TSHR (0.49) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL30675403 | 0.65 | TSHR (0.75) | TSHRSMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218341-B1 | SULFONYL CARBOXAMIDE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-6552048-B2 | For use in therapy of hyperlipidemia and arteriosclerotic disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-22 | — | — | US | disclosed |
| US-20020147337-A1 | Process for preparing sulfonylcarboxamide derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-10 | — | — | US | disclosed |
| WO-2002072538-A1 | IMPROVED METHOD FOR PRODUCING SULFONYL CARBOXAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| EP-1218341-A1 | SULFONYL CARBOXAMIDE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| US-20020072520-A1 | Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6342512-B1 | ANTILIPEMIC AGENTS, ATHERIOSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-29 | — | — | US | disclosed |
| WO-2001016094-A1 | SULFONYL CARBOXAMIDE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072520-A1 | Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals | LIPA, CES1, SLC5A1 | TSHR 1486/4885SMN1; SMN2 2022/4885CA12 3421/4885 |
| US-20020147337-A1 | Process for preparing sulfonylcarboxamide derivatives | SLC5A1, CES1, SLC5A2 | TSHR 2243/4885SMN1; SMN2 1548/4885CA12 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.